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Abstract A gene, blmA, from bleomycin (Bm)-producing
Streptomyces verticillus, encodes a Bm-binding protein, desig-
nated BLMA. The expression of BLMA conferred resistance to
Bm in the Escherichia coli host, whereas a mutant protein,
designated Pro-9/Leu, with the N-terminal proline 9 residue in
BLMA replaced by leucine, did not. We created a fusion protein
between the maltose-binding protein (MBP) and a mutant
protein Pro-9/Leu/Leu with Met-94 in Pro-9/Leu replaced by
leucine. Pro-9/Leu/Leu from the fusion protein, obtained by
digestion with CNBr digestion, did not inhibit DNA-cleaving and
antibacterial activities of Bm. Native-polyacrylamide gel elec-
trophoresis (PAGE) and gel filtration column chromatographic
analysis showed that the molecular size of Pro-9/Leu/Leu is
roughly half of that of BLMA, suggesting that the mutant
protein cannot form dimeric structure. Furthermore, Far-UV
circular dichroism (CD) spectrum of Pro-9/Leu/Leu was quite
different from that of BLMA and similar to the spectra obtained
from unordered proteins [Venyaminov, S.Y. and Vassilenko,
K.S. (1994) Anal. Biochem. 222, 176^184], suggesting that the
secondary structure of Pro-9/Leu/Leu is disrupted. These results
indicate that the mutation abolishes not only dimer formation but
also the secondary structure of BLMA, which results in the loss
of its function as a Bm-resistance determinant.
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1. Introduction
Since bleomycin (Bm) and its related antibiotics cause nu-
cleotide sequence-speci¢c DNA cleavage and inhibit the
growth of both bacterial and mammalian cells [1], they are
used to treat human malignancies. The DNA-cleaving process
seems to be mediated via a Fe2 chelate of Bm that is capable
of generating a reduced form of oxygen in proximity to sus-
ceptible site(s) in the DNA [2]. To understand how Bm-pro-
ducing micro-organism are protected from the lethal e¡ect of
their own product, we have cloned genes encoding Bm-resist-
ance determinants from Bm-producing Streptomyces verticil-
lus ATCC15003 [3]. We have found that the two independent
cloned genes, designated blmA and blmB, encode a Bm-bind-
ing protein and a Bm N-acetyltransferase, respectively [3,4].
The blmA consists of a 366 bp open reading frame and
encodes an acidic protein consisting of 122 amino acids with
a calculated molecular size of 13179 daltons. We have over-
produced and physico-chemically characterized the blmA gene
product, designated BLMA [5]. Moreover, we have crystal-
lized BLMA [6] and determined in detail the X-ray crystal
structure at a high resolution of 1.5 Aî (submitted), showing
that BLMA forms a dimeric structure through N-terminal
arm-exchange. The resulting concavity and groove may con-
tribute to trapping two Bm molecules. That is, the formation
of dimeric structure may be necessary to retain an a⁄nity for
Bm.
Proline appears to play a key role in the L-strand of the
hinge peptide that in bovine seminal ribonuclease A [7] and
tumor necrosis factor [8] links the exchangeable N-terminal
segment to its subunit body. Therefore, we hypothesized
that the N-terminal proline 9 residue in BLMA may play a
role as a hinge to form its dimeric structure. In this study we
created mutant BLMAs, with Pro-9 of BLMA replaced by
one of several amino acids and examined whether the mutant
protein loses function as a Bm-resistance determinant.
2. Materials and methods
2.1. Bacterial strains and plasmid
E. coli TB1 and plasmid pMAL-c2 [9] were used for the expression
of blmA or its mutant gene fused to a maltose-binding protein (MBP)
gene, malE. E. coli strains DH5K and BMH71-18 were used for site-
directed mutagenesis.
2.2. Site-directed mutagenesis and DNA sequencing
The gene blmA, contained in the EcoRI-BamHI fragment of plas-
mid pKM10 [6], was subcloned into the pUC18 to generate pUC-
blmA. The chimeric plasmid was used for site-directed mutagenesis
using transformer site-directed mutagenesis kit (Clonetech, USA).
To con¢rm the mutation in blmA, DNA sequence was determined
by the dideoxy chain termination method [10] with the ALF-II auto-
matic sequencer (Pharmacia Biotech, Sweden) using the AutoRead
Sequencing Kit (Pharmacia Biotech).
2.3. Assay of Bm resistance
E. coli HB101 carrying blmA or its mutant gene, inserted into plas-
mid pKKtrp [5], was cultured in M9-casamino acid medium [11] sup-
plemented with Bm (100 Wg/ml) and 3-indoleacrylic acid (25 Wg/ml) as
an inducer of the trp promoter. E. coli TB1 harboring blmA or its
mutant gene, fused to malE, was cultured in Luria-Bertani (LB) me-
dium [11] supplemented with Bm (100 Wg/ml). The induction of the
tac-controlled gene expression was done by addition of 1 mM iso-
propyl-L-thiogalactopyranoside (IPTG).
2.4. Western blotting
E. coli HB101 harboring blmA or the mutant gene was washed
twice with bu¡er A (20 mM Tris-HCl (pH 7.5), 2 mM EDTA, and
2 mM 2-mercaptoethanol) and suspended in the same bu¡er. The
washed cells were sonicated (Bioruptor, Cosmo Bio, Japan) and cen-
trifuged at 10 000Ug for 20 min. The protein concentration of the
resulting supernatant £uid was determined according to the method
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[12], and subjected to Tricine-SDS-PAGE [13]. The proteins in the gel
were electrophoretically transblotted onto a nitrocellulose membrane
(Hybond-C super, Amersham) and detected with Elite ABC kit (Vec-
tastain, USA) using an anti-BLMA monoclonal antibody described
previously [5].
2.5. CD spectrum
After BLMA or Pro-9/Leu/Leu was dissolved in 1 mM Tris-HCl
(pH 7.5) at a concentration of 5 WM, its CD spectrum was measured
using a spectrophotometer (Model J-720, Jasco, Japan) at the range
between 250 and 185 nm.
2.6. Native-PAGE
Native-PAGE of the protein was performed according to [14]. The
proteins were stained with Coomassie brilliant blue R-250.
3. Results and discussion
3.1. Bm resistance of E. coli harboring the mutant blmA
The monomeric form of BLMA consists of three K-helices
and two anti-parallel L-strands, in addition to two short L-
strands (L1 and L2) twisting at its N-terminal proline 9, des-
ignated Pro-9 (submitted). The dimeric form, generated by the
alternate arm-exchange of the monomeric BLMA molecule,
results in a large concavity and a long groove which may trap
two molecules of Bm (Fig. 1). The X-ray crystallography sug-
gested that Pro-9 plays a role as a hinge to support the di-
meric structure. To con¢rm this hypothesis, we generated sev-
eral mutant proteins with Pro-9 in BLMA replaced by some
amino acids using the site-directed mutagenesis technique. A
codon CCC for Pro was replaced by GGC, CAG, CTG, TAC,
or GCT which is corresponded to Gly, Gln, Leu, Tyr, and
Ala, respectively, according to the codon usage of E. coli.
Each mutant blmA, con¢rmed by the nucleotide sequence de-
termination, was placed under control of the trp promoter in
the plasmid pKKtrp [5] and introduced into E. coli HB101. E.
coli producing BLMA or Pro-9/Ala was resistant to 100 Wg/ml
of Bm, but the same hosts producing other mutant proteins
were not (Fig. 2A). The minimum inhibitory concentration
(MIC) of Bm against E. coli carrying each mutant blmA ex-
cept Pro-9/Ala-encoding gene was the same as that of the host
cell. Although E. coli carrying blmA overproduced BLMA,
the same cells transformed with the mutant blmA, even the
Pro-9/Ala-encoding gene, produced at a lower level, as de-
tected by Western blot analysis (Fig. 2B).
Fig. 3A shows that each mutant blmA, replacing Pro-9 in
BLMA by Gly, Gln, Leu, Tyr, or Ala, was overexpressed at
the same level when fused to malE as a reporter gene. The
Pro-9/Ala-producing E. coli exhibited the same Bm resistance
as in the case of the direct expression manner under the con-
trol of trp promoter (Fig. 3B), whereas Pro-9/Gly, Pro-9/Gln
and Pro-9/Tyr mutant-producing cells showed moderate re-
sistance to Bm. Although the solubility of BLMA derivatives
might a¡ect the Bm-resistance phenotype, all mutant BLMAs
were similarly soluble. These suggest that the binding a⁄nity
of these mutant proteins for Bm might be lower than that of
the wild-type. Interestingly, the growth of E. coli expressing
Pro-9/Leu was completely inhibited by 100 Wg/ml of Bm, in-
dicating that this protein had lost function as a Bm-resistance
determinant.
Fig. 1. A ribbon model of the BLMA dimer. Two monomers were
indicated by red and green color. The dimeric structure was formed
through the alternate arm-exchange. The N-terminal proline 9 indi-
cated by an arrow is positioned at the hinge between two mono-
mers.
Fig. 2. Bm-resistance pro¢le of E. coli harboring each mutant blmA
expressed under control of the trp promoter (A) and production of
the corresponding proteins (B). A: E. coli harboring wild-type and
each mutant blmA under control of the trp promoter were cultured
in M9-casamino acid medium supplemented with Bm (bleomycin A2
sulfate, 100 Wg/ml) and IAA (25 Wg/ml). The cell growth was moni-
tored by the absorbance at 600 nm at the given times. B: Western
blot analysis of the proteins produced by E. coli harboring wild-
type or each mutant blmA under control of the trp promoter. lanes:
1, wild-type; 2, Pro-9/Gly; 3, Pro-9/Ala; 4, Pro-9/Gln; 5, Pro-9/
Leu; 6, Pro-9/Tyr.
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3.2. Physico-chemical properties of the Pro-9/Leu protein
A fusion protein composed of the MBP and Pro-9/Leu,
contains a recognition site for cleavage by a blood coagula-
tion factor Xa protease. But the fusion protein was unexpect-
edly not cleaved into the two domains. Since BLMA has
methionine residues at 1st and 94th position from the N-ter-
minus, we designed a mutant fusion protein between the MBP
and Pro-9/Leu cleaved by digestion with cyanogen bromide
(CNBr): that is, the double mutant protein, designated Pro-9/
Leu/Leu, replacing Met-94 in Pro-9/Leu by Leu was generated
by site-directed mutagenesis and fused to MBP. The Pro-9/
Leu/Leu-encoding gene fused to malE was overexpressed in E.
coli TB1. We preliminarily con¢rmed that E. coli transformed
with a mutant protein-encoding gene, replacing Met-94 in
BLMA by Leu, overproduced the protein under control of
the trp promoter and exhibited resistance to Bm at the same
level as the cell transformed with blmA. Since the MBP and
Pro-9/Leu/Leu domains in the fusion protein have six Met
and one N-terminal Met, respectively, Pro-9/Leu/Leu can be
cut out by digestion of the fusion protein with CNBr. The
digests were dialyzed against 20 mM Tris-HCl (pH 8.0), sub-
jected to a ResourceQ ion-exchange HPLC column (Pharma-
cia Biotech) and eluted with 20 mM Tris-HCl (pH 8.0) con-
taining 0^0.5 M NaCl to purify to homogeneity (Fig. 4).
Although, Pro-9/Leu/Leu in the CNBr-treated protein mixture
(Fig. 4, lane 4) migrated more slowly than the puri¢ed protein
(Fig. 4, lane 5), Western blot analysis con¢rmed their identity.
The N-terminal amino acid sequence of Pro-9/Leu/Leu was
determined and con¢rmed using Model A490 automatic pro-
tein sequencer (PE Applied Biosystems, USA).
The Pro-9/Leu/Leu did not inhibit the DNA-cleaving and
antibacterial activities of Bm (data not shown), suggesting
that the mutant protein may have lost the binding ability
for Bm. The lack of the Bm-binding ability of Pro-9/Leu/
Leu was not due to the denaturation of the protein, because
fully active BLMA was puri¢ed from the fusion protein by the
same method as used for Pro-9/Leu/Leu. Although Tricine-
SDS-PAGE analysis showed that BLMA and Pro-9/Leu/Leu
migrate equally, native-PAGE analysis revealed that Pro-9/
Leu/Leu migrated more quickly on the gel than that of
BLMA (data not shown). The molecular size of BLMA, de-
duced from the nucleotide sequence of blmA, is 13 197 dal-
tons. A gel ¢ltration analysis by fKTA explorer system
(Amersham Pharmacia Biotech) using a HiLoad 26/60 Super-
dex 75 column showed that the molecular size of BLMA is
approximately 30 kDa, apparently forming dimeric structure,
whereas that of Pro-9/Leu/Leu is approximately 20 kDa.
These results suggest that the mutant protein can not form
the dimeric structure. Fig. 5 shows CD spectra of Pro-9/Leu/
Leu and BLMA. The spectrum of BLMA showed two nega-
Fig. 3. Overproduction of mutant BLMAs fused with maltose-bind-
ing protein and Bm-resistance pro¢le of E. coli producing the fusion
proteins. A: Tricine-SDS-PAGE of the proteins from E. coli harbor-
ing wild-type and each mutant blmA fused with malE gene. lanes:
1, molecular size marker; 2, host; 3, wild-type; 4, Pro-9/Gly;
5, Pro-9/Ala; 6, Pro-9/Gln; 7, Pro-9/Leu; 8, Pro-9/Tyr. B: E. coli
harboring wild-type or each mutant blmA fused with malE were
grown in LB medium supplemented with Bm (100 Wg/ml) and IPTG
(1 mM). The cell growth was monitored by the absorbance at
600 nm at the given times.
Fig. 4. Puri¢cation of Pro-9/Leu/Leu. The proteins at several puri¢-
cation steps of Pro-9/Leu/Leu were analyzed by Tricine-SDS-PAGE.
Lanes: 1, molecular size marker; 2, the cell extracts from E. coli
harboring the double mutant blmA (Pro-9/Leu/Leu) fused with
malE ; 3, the fusion protein; 4, the fusion protein cleaved with
CNBr; 5, the puri¢ed Pro-9/Leu/Leu.
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tive bands at 222 and 208^210 nm and one positive band near
195 nm. This is typical to the spectra of K+L- or K/L-proteins
[15]. On the other hand, the spectrum of Pro-9/Leu/Leu was
quite di¡erent from that of BLMA. A strong negative band
near 205 nm characterizing the mutant protein was similar to
those of unordered proteins [15], suggesting that the sec-
ondary structure of Pro-9/Leu/Leu may be disrupted. This
result indicates that the replacement of Pro-9 by Leu in
BLMA may a¡ect not only the dimeric formation but also
the folding of the protein.
The crystal structure of BLMA forms dimeric structure
through an alternate arm-exchange composing of the N-ter-
minal eight amino acid residues in BLMA monomeric protein
(submitted). Moreover, the N-terminal Pro-9 may play a role
as a hinge to support the dimeric structure. The present study
shows that the replacement of Pro-9 in BLMA by Leu abol-
ishes the binding a⁄nity for Bm due to the disruption of the
dimeric formation. Since the crystal structure of BLMA pre-
dicts that small amino acids, such as Ala and Ser, can ¢t into
the space of Pro-9, it is easy to understand how Pro-9/Ala can
retain an a⁄nity for Bm, but Pro-9/Leu does not.
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